|
|
|
|
| LEADER |
00000cam a2200000 a 4500 |
| 001 |
1348293 |
| 003 |
ICU |
| 005 |
19990728113200.0 |
| 008 |
920708s1992 cau b 001 0 eng c |
| 010 |
|
|
|a 91005085
|
| 020 |
|
|
|a 0804716692 (cloth : alk. paper) :
|c $30.00
|
| 035 |
|
|
|a (ICU)BID15911110
|
| 035 |
|
|
|a (OCoLC)24376708
|
| 040 |
|
|
|a DNLM/DLC
|c DLC
|d DLC$dOrLoB
|
| 043 |
|
|
|a d------
|
| 050 |
0 |
0 |
|a HD9674.D44
|b S54 1992
|
| 060 |
|
|
|a QV 736 S587b
|
| 082 |
|
|
|a 338.4/76151/091724
|2 20
|
| 100 |
1 |
|
|a Silverman, Milton,
|d 1910-
|1 http://viaf.org/viaf/45574724
|
| 245 |
1 |
0 |
|a Bad medicine :
|b the prescription drug industry in the Third World /
|c Milton Silverman, Mia Lydecker, Philip R. Lee.
|
| 260 |
|
|
|a Stanford, Calif. :
|b Stanford University Press,
|c 1992.
|
| 300 |
|
|
|a xvii, 358 p. ;
|c 24 cm.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|0 http://id.loc.gov/vocabulary/contentTypes/txt
|
| 337 |
|
|
|a unmediated
|b n
|2 rdamedia
|0 http://id.loc.gov/vocabulary/mediaTypes/n
|
| 338 |
|
|
|a volume
|b nc
|2 rdacarrier
|0 http://id.loc.gov/vocabulary/carriers/nc
|
| 504 |
|
|
|a Includes bibliographical references (p. [319]-339) and index.
|
| 505 |
0 |
0 |
|g 1.
|t The Patients: Health for All By--When?
|t Disaster in the 1980s.
|t An Excess of Illness --
|g 2.
|t Drug Labeling: How Safe? How Deadly?
|t The Latest Round.
|t Drugs Against Fever and Pain.
|t Antiarthritis Drugs.
|t Antidiarrhea Agents.
|t Anti-bacterials.
|t Appetite Stimulants.
|t Cardiovascular Agents.
|t Cerebral Vasodilators.
|t Major Tranquilizers.
|t Minor Tranquilizers.
|t Antidepressants.
|t Anabolic Steroid.
|t Female Sex Hormones.
|t "Sex Tonics"
|t Trouble in Africa--Again.
|t An Evident Change --
|g 3.
|t The Companies: Heroes Or Villains?
|t Anatomy of the Drug Industry.
|t End of the Glory Days.
|t Essential Drugs Lists.
|t Patent Infringement.
|t Storm over Mr. Medawar.
|t An Alternative Voice from the Industry --
|g 4.
|t The Great Generics Controversy.
|t The Antigenerics Rumors.
|t Generics Overseas.
|t The Generic Drugs Scandal.
|t The Dingell Committee Drug Hearings.
|t Shortcut to Drug Approval.
|t A Search for the Culprit.
|t Generics in the Philippines --
|g 5.
|t The Dipyrone Affair.
|t The Curious Case of Paracetamol.
|t The Entrance of Dipyrone.
|t The Matter of Merital.
|t The Thailand Debacle --
|g 6.
|t The Case of the Deadly Pregnancy Test.
|t The Campaign Against High-Dosage Products.
|t The Public Hearings.
|t The Party Lines.
|t Finally, the Verdict --
|g 7.
|t Bangladesh and the Noble Experiment.
|t The Experiment Is Launched.
|t The Experiment Explodes.
|t The Experiment Pays Off --
|g 8.
|t The Drug Swindlers.
|t Deceit in Indonesia.
|t Incident in India.
|t Drug Fraud Brasileiro Style --
|g 9.
|t So Shines a Good Deed.
|t A Better Drug Chain.
|t The Essential Generics War.
|t The Tropicare Project.
|t The Damn Fly and Its Worms --
|g 10.
|t Ammunition for the Consumers.
|t The Task Force Reports.
|t The "Drugging" Books.
|t The Marketing Codes.
|t The Consumerist Campaigns.
|t The HAI Proposals --
|g 11.
|t Consumer Power: The Hansson/Ciba-Geigy Connection.
|t The Appearance of SMON.
|t Start of the Damage Suits.
|t The Tanabe and Takeda Apologies.
|t Hansson and the Press.
|t Threat of a Boycott.
|t The Ciba-Geigy Meetings.
|t The Butazone Confrontation.
|t Problems with Mr. Knop.
|t Failed Mission, But-- --
|g 12.
|t The Essential Role of Government.
|t Regulation in the United States.
|t The Dreadful Drug Lag.
|t Regulation by Persuasion.
|t The Nairobi Nonconfrontation.
|t Export of Unapproved Drugs --
|g 13.
|t Hard Choices.
|t Problems Related to the Crisis.
|t The Silverman, Lydecker, and Lee Studies.
|t The Work of Many.
|t The Problems at Hand.
|t The Matter of Quality Assurance.
|t Essential Drugs Lists: Some Progress.
|t The Matter of Bribery.
|t Domestic Drug Industries: Some Hard Choices.
|t External Vigilance, Unending Consultation --
|t Appendix: Tables of Product Indications, Contraindications, and Warnings.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|z Developing countries
|x Corrupt practices.
|
| 650 |
|
0 |
|a Pharmaceutical policy
|z Developing countries.
|
| 650 |
|
2 |
|a Drug Industry
|x standards
|
| 651 |
|
2 |
|a Developing countries
|
| 650 |
|
7 |
|a Pharmaceutical industry
|x Corrupt practices.
|2 fast
|0 http://id.worldcat.org/fast/fst01060133
|
| 650 |
|
7 |
|a Pharmaceutical policy.
|2 fast
|0 http://id.worldcat.org/fast/fst01060194
|
| 651 |
|
7 |
|a Developing countries.
|2 fast
|0 http://id.worldcat.org/fast/fst01242969
|
| 700 |
1 |
0 |
|a Lydecker, Mia,
|d 1926-
|0 http://id.loc.gov/authorities/names/n82022564
|1 http://viaf.org/viaf/263277518
|
| 700 |
1 |
0 |
|a Lee, Philip R.
|q (Philip Randolph),
|d 1924-
|0 http://id.loc.gov/authorities/names/n80062918
|1 http://viaf.org/viaf/33296294
|
| 850 |
|
|
|a ICU
|
| 901 |
|
|
|a ToCBNA
|
| 903 |
|
|
|a HeVa
|
| 929 |
|
|
|a cat
|
| 999 |
f |
f |
|i 16f969c2-10dc-57cd-8db9-a8679507dfd6
|s 5848a4c2-c53e-5f45-abcf-35392bdc5b7e
|
| 928 |
|
|
|t Library of Congress classification
|a HD9674.D44S540 1992
|l JRL
|c JRL-Gen
|i 2190990
|
| 927 |
|
|
|t Library of Congress classification
|a HD9674.D44S540 1992
|l JRL
|c JRL-Gen
|b 36474505
|i 2691253
|
